skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging

Abstract

Antibodies against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide. No Drawings

Inventors:
Issue Date:
OSTI Identifier:
6925998
Patent Number(s):
5346687 A
Application Number:
PPN: US 7-816476
Assignee:
Rhomed Inc., Albuquerque, NM (United States)
DOE Contract Number:  
FG04-89ER60899
Resource Type:
Patent
Resource Relation:
Patent File Date: 3 Jan 1992
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIBODIES; LABELLING; ANTIGEN-ANTIBODY REACTIONS; DIAGNOSTIC USES; IMAGE PROCESSING; PROCESSING; USES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics

Citation Formats

Rhodes, B A. Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging. United States: N. p., 1994. Web.
Rhodes, B A. Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging. United States.
Rhodes, B A. Tue . "Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging". United States.
@article{osti_6925998,
title = {Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging},
author = {Rhodes, B A},
abstractNote = {Antibodies against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide. No Drawings},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {1994},
month = {9}
}